Clinical Trials on Embryonal Carcinoma in China

Total 5597 results

Guangdong Provincial People's Hospital
Novartis

Unknown

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Neuroendocrine Tumors | Carcinoid Tumor

China
Peking Union Medical College Hospital

Recruiting

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Gastrointestinal Neuroendocrine Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma

Gastric Neuroendocrine Carcinoma

China
Hutchison Medipharma Limited

Recruiting

A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma

China
Peking University

Terminated

Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma

Neuroendocrine Carcinoma

China
Peking University

Unknown

Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

Neuroendocrine Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Peking University

Unknown

Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

Neuroendocrine Carcinoma

China
Fujian Medical University

Completed

the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma

Gastric Neuroendocrine Carcinoma

China
Wuhan Union Hospital, China

Not yet recruiting

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Advanced Melanoma | Advanced Urothelial Carcinoma

China
Peking University
Qilu Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma

Neuroendocrine Carcinoma

China
Huazhong University of Science and Technology

Not yet recruiting

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Advanced or Metastatic EP-NEC

China
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Neuroendocrine Tumors | Neuroendocrine Carcinoma

China
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3

China
Peking University

Unknown

Octreotide LAR as Maintenance Treatment for Patients With NEC

Esophageal Neuroendocrine Carcinoma | Gastro-entero-pancreatic Carcinoma

China
Peking University

Recruiting

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Neuroendocrine Carcinoma of the Bladder

China
Fudan University

Completed

Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)

Cisplatin | Adenoid Cystic Carcinomas

China
Peking University Third Hospital

Recruiting

RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes

Squamous Cell Carcinomas | Brachytherapy

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Melanoma | Urothelial Carcinoma

China
Lei Li

Unknown

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Chemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 Antibody

China
Tianjin Medical University Cancer Institute and...

Recruiting

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Pancreatic Carcinoma | Neuroendocrine Carcinoma | Neuroendocrine Tumor Grade 3

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Small Cell Lung Cancer | Neuroendocrine Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Small Cell Lung Cancer | Neuroendocrine Cancer

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Medullary Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Adrenal Cortical Carcinoma | Thymic Neuroendocrine Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Head and Neck Squamous Cell Carcinomas

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China
Hospital of Stomatology, Wuhan University

Recruiting

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

Clinical IVb Stage Oral Squamous Cell Carcinomas Patients

China
Fudan University

Recruiting

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Non-small Cell Lung Cancer | Neuroendocrine Carcinoma | Histology Transformation

China
RenJi Hospital

Recruiting

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma (RJBLC-NEBC001)

Bladder Cancer | Neuroendocrine Carcinoma of the Bladder

China
Shanghai Simnova Biotechnology Co.,Ltd.
Shanghai Chest Hospital

Recruiting

SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shenzhen Sixth People's Hospital; Zhongshan People's Hospital, Guangdong, China

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Not yet recruiting

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Malignant Glioma of Brain | Gastric Carcinoma | Colorectal Carcinoma

China
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Unknown

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

Small Cell Lung Cancer | Glioblastoma | Medulloblastoma | Neuroendocrine Neoplasm | Basal Cell Carcinoma | Adenocarcinoma of Esophagogastric Junction

China
Fuzhou General Hospital

Recruiting

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Esophageal Squamous Cell Carcinomas

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Recruiting

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Neoplasms | Neoplasm Metastasis | Metastatic Gastrointestinal Carcinoid Tumor

United States, China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Fudan University
KAEDI

Recruiting

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
Jiujiang University Affiliated Hospital
KAEDI

Withdrawn

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Hepatocellular Carcinoma | Malignant Glioma of Brain | Non-small Cell Lung Cancer | Gastric Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas

Salivary Gland Carcinomas

China
Eye & ENT Hospital of Fudan University
Changhai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaborators

Recruiting

Clinical Treatments in Specialized Disease of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)

Glottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall Carcinoma

China
Peking University Cancer Hospital & Institute
Peking University Health Science Center

Recruiting

68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy

Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)

Medullary Thyroid Carcinoma

China
National Cancer Institute (NCI)

Completed

Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China

Nasopharyngeal Cancinoma (NPC)

China
Taizhou Hanzhong biomedical co. LTD

Not yet recruiting

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Sunitinib Malate Capsules.

Renal Cell Carcinoma | Gastrointestinal Stromal Tumors | Pancreatic Neuroendocrine Tumor

China

Clinical Trials on Embryonal Carcinoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations